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Objective. The aim of this study is to measure the reliability and external validity of AMSTAR by applying it to a sample of TCM
systematic reviews. Study Design and Methods. We tested the agreement, reliability, construct validity, and feasibility of AMSTAR
through comparisons with OQAQ. Statistical analyses were performed by using SPSS 13.0. Results. A random of sample with 41
TCM systematic reviews was selected from a database. The interrater agreement of the individual items of AMSTAR was moderate
with a mean kappa of 0.50 (95% CI: 0.26, 0.73). The ICC for AMSTAR against OQAQ (total score of 9 items, excluding item 10)
was 0.87 (95% CI: 0.76, 0.93). Conclusions. Although there is room for improvement on few items, the new tool is reliable, valid,
and easy to use for methodological quality assessment of systematic reviews on TCM.
1.Introduction
Traditional Chinese medicine (TCM) is one of the rarely
existing traditional medicines that hold systematic theories
as well as preventative and therapeutic methods for diseases
in practice [1]. Since the 1950s, research methods in
modern medicine (Western medicine) have been gradually
introduced to TCM studies; the ﬁrst TCM systematic review
appeared in medical journals in the late 1990s, and now
hundreds to thousands of reviews have been published on
the area of TCM [2, 3]; systematic reviews have become the
standard approach in assessing and summarizing primary
studies. However, even though systematic reviews proved to
be useful, serious consideration must be given to how they
were conducted; high methodological quality of systematic
reviews is a prerequisite for recommendation of the use
or avoidance of a TCM intervention. At present, either
researches or methods for assessing quality of systematic
reviews are still not fully developed in TCM and there is
substantial room for improvement [2, 3]; even in Western
medicine current instruments for assessing methodological
quality of systematic reviews are still suboptimal and need
revision and updating [4, 5]. A new tool termed AMSTAR,
an acronym for “a measurement tool to assess systematic
reviews,” was developed strictly upon the OQAQ (Overview
Quality Assessment Questionnaire) [6], the Sack checklist
(quality assessment checklist) [7], and three additional
items. This tool is an 11-item questionnaire requiring
assessors to answer “yes,” “no,” “cannot answer,” or “not
applicable”; and a recent study reported that AMSTAR has
good agreement, reliability, construct validity, and feasibility
to assess the quality of systematic reviews [8]. However,
these psychometric properties within AMSTAR were tested
by having it apply to only a limited set of systematic reviews
from Western medicine; a further step is needed to assess its
validity and reliability, by a broader range of assessors and
more samples of reviews in diverse circumstances [8]. Will
the results be reproducible when assessing methodological
quality of systematic reviews on traditional chinese medicine
(TCM)? The answer is not clear yet, further validation is
necessary. The aim of this study is to validate the reliability
and external validity of AMSTAR by applying it to a sample
of TCM systematic reviews.
2.MaterialsandMethods
2.1. Identiﬁcation and Inclusion of Systematic Reviews on
TCM. WehaveadoptedthedeﬁnitionsusedbytheCochrane2 Evidence-Based Complementary and Alternative Medicine
Collaboration: a systematic review is a review of a clearly
formulated question, that which uses systematic and explicit
methods to identify, select, and critically appraise relevant
researches, and to collect and analyze data from the studies
included in the review [9]. Then a search strategy for
locatingsystematicreviewsonTCMwasformulatedbyusing
the deﬁnitions; search terms included “Chinese medicine”,
“Chinese herb”, “plant preparations”, “Chinese medical for-
mula,”“metaanalysis,”“meta-analysis,”“meta-analyses,”and
“systematic review.” We performed a comprehensive search
on CNKI (China National Knowledge Infrastructure), CBM
(Chinese Biomedical Database), VIP (Chongqing VIP peri-
odicals Database), Medline and EMbase databases (January
1, 1999 to the end of 2008) in addition to hand search on
Chinese Journal of Evidence-Based Medicine (incept to the
end issue of 2008), Chinese Journal of Integrated Traditional
andWesternMedicine (fromtheﬁrstissuein1999 totheend
issue in 2008), and Journal of Chinese Integrative Medicine
(from the ﬁrst issue in 1999 to the end issue in 2008). Two
reviewers screened the titles and abstracts of identiﬁed stud-
ies independently, disagreement was resolved by discussion.
A total of 165 systematic reviews on TCM were included, full
detail of evaluations has been reported separately [10]. We
used a computer-generated random sample (approximately
25% of the 165 systematic reviews)as a testset forvalidation.
2.2. Data Extraction. We tested the agreement, reliability,
construct validity, and feasibility of AMSTAR through com-
parisons with OQAQ, the latter was a validated scale (over-
view quality assessment questionnaire, OQAQ) developed
by Oxman and Guyatt in 1991 [6]. The OQAQ scale
measures across a continuum using nine questions (items 1–
9) designed to assess various aspects of the methodological
quality of systematic reviews and the tenth item requires
assessors to assign an overall quality score on a seven-point
scale [6].
In order to adhere more faithfully to the guidance
provided by AMSTAR and OQAQ, two assessors (KDY, WY)
performed a separate translation and conducted a pilot test
independently. Each translator prepared a separate transla-
tion and the diﬃculty in obtaining conceptually equivalent
expressions in Chinese was assessed too; subsequently, a
sampleof2systematicreviewsonTCMwastakentoperform
pilot test by two authors independently; based on the results
and consensus from reviewers, the ﬁnal Chinese versions
of AMSTAR and OQAQ were then developed for formally
evaluating methodological quality of Chinese systematic
reviews; all inconsistencies identiﬁed either in translation or
in application were resolved by discussion. On the basis of
this, we constructed a data extraction form in Chinese for
this study, in which 11 items of AMSATR and 10 items of
OQAQ were adopted directly. In addition, publication status
and reporting characteristics of systematic reviews, such as
publish language, number of pages, funding source, update
ornot,Cochranesystematicreviewornot,targetdisease,and
institution of ﬁrst author, were also incorporated; besides,
the time required to complete an assessment while applying
AMSTAR and OQAQ was recorded too.
2.3. Agreement and Reliability. Assessors were required to
answer “yes” score or any other scores for each of items
(AMSTAR and OQAQ). If an item was scored “yes,” it would
be given one point, otherwise, 0 point. We added up these
to calculate a total score, the reliability of this total score
was assessed through calculating intraclass correlation coef-
ﬁcients; the agreement for each item and the overall tool was
explained by percentage of actual agreement as well as Kappa
coeﬃcient [5, 8]. Kappa coeﬃcient is a popular measure
for chance-corrected nominal scale agreement between two
raters. We adopted the Kappa values of <0 rates as less
than chance agreement, 0.01–0.20 as slight agreement, 0.21–
0.40 as fair agreement, 0.41–0.60 as moderate agreement,
0.61–0.80 as substantial agreement, and 0.81–0.99 as almost
perfect agreement [8].
2.4. Validity and Feasibility. The OQAQ was selected as a
criterion tool because it had been rigorously developed, its
face validity was strong, and its validity had been thoroughly
tested [6]. We assessed construct validity by comparing
AMSTAR, OQAQ, and a self-developed global assessment
scale. Construct validity was showed by intraclass correlation
coeﬃcient (ICC); for the purpose of calculating ICC, we
adopted methods used by the AMSTAR group [8], and
converted the mean total scores (mean of two assessors) of
per review to the percentage of maximum score (11 points in
AMSTAR and 9 points in OQAQ accordingly); in addition,
we developed a 100-point rating scale for overall quality
assessment based on answers to the eleven questions in
AMSTAR, in which two assessors indicated his or her judg-
ments by checking tick-marks on a horizontal line (0 to 100
point), an SR without any ﬂaws would be scored 100 points.
Meanwhile, we also adopted the item 10 in OQAQ as a vali-
dated global assessment instrument. The overall mean scores
(mean of two assessors), either using the self-developed 100-
point rating scale or using the item 10 from OQAQ, were
also taken to verify the construct validity of AMSTAR. The
feasibility of AMSTAR was assessed by recording the time it
took to complete scoring, and paired t-test or nonparametric
test was applied when comparing with OQAQ.
Database was established by using an electronic form
on Microsoft Excel 2003 (Microsoft Corp., Redmond, WA);
the data set extracted contained two quality ratings for each
review, yielding a total of four ratings per review. Data
analysis was performed by SPSS 13.0 (SPSS, Chicago, IL).
P<0.05 was considered signiﬁcant.
3. Results
A random sample with 41TCM systematic reviews was
selected from a database developed in a previous study [10].
Of which, only 9 reviews were written in English, and the
majority (78%) was published in Chinese journals [11–51].
Thesampleincluded35paper-basedreviewsand6Cochrane
reviews; there was only one updated Cochrane review.
According to the International Classiﬁcation of Diseases
10 (ICD-10), the topics of the reviews ranged across 9
systems,andmainlyfocusedondiseasesofcirculatorysystemEvidence-Based Complementary and Alternative Medicine 3
(15SRs or 37% of the sample, such as stroke and other
cardiovascular diseases), infectious and parasitic diseases
(7SRs, like HBV, SARS), genitourinary system (5SRs, such
as ectopic pregnancy), digestive system (4SRs, like ulcerative
colitis), nervous system (3SRs, such as Parkinson’s disease),
and musculoskeletal system and connective tissue (3SRs,
osteoporosis). The number of pages of included TCM SRs
ranged widely from 2 to 80 with a median of 6 pages, of
which, Cochrane systematic reviews had more pages than
non-Cochrane reviews (P<0.001), with medians of 31
(range: 16–80) and of 5 (range: 2–11), respectively. Less than
half of the reviews (41.5%) were presented by clinicians.
T o t a lm e a ns c o r e so nA M S T A Rr a n g e df r o m2t o1 0( o u t
of a maximum score of 11) with a mean percentage score of
55.1%. The total mean quality scores on OQAQ ranged from
3 to 8 (out of a maximum score of 9) with a mean percentage
score of 63.6%. The overall scores for the global assessment
instrument (item 10 in OQAQ) ranged from 1 to 6 (out of a
maximum score of seven) with a mean of 3.3 (95% CI: 2.9,
3.6), and overall scores using the self-developed 100-point
rating scale ranged from 15 to 73 with a mean of 47.6 (95%
CI: 43.4, 51.7).
3.1. Agreement and Reliability. Substantial agreements
(>80% or nearly 80%) were observed in majority of the
individual items (item 1, 2, 3, 4, 6, 7, 8, 10, 11) on AMSTAR,
with a mean percentage of 84% (95% CI: 71.1%–91.9%);
agreements on item 5 and item 9 were mild at a percentage
of less than 60%. Kappa ranged widely from −0.03 to 1.00
with a mean of 0.50 (95% CI: 0.26, 0.73); ﬁve items (item 2,
3, 4, 10, 11) scored a kappa of >0.70 (0.70 to 1.00); the highly
agreements in four items (item 1, item 6, item 7, item 8)
ranged from 80% to 95% and inversely low kappa (−0.034,
0.40,0.36,0.36)maybeexplainedbyaskeweddistributionof
responses, that is, approximately 80% (in item 6) to 90% (in
item 1, 7, 8) of reviews in which the assessors agreed on the
score “yes.” However, items 5 (list of included and excluded
studies) and 9 (appropriate method to combine studies)
scored relative low either in agreement percentage or in
kappa parameter (Table 1). Agreements on individual items
of OQAQ were inferior to AMSTAR, with a mean percentage
of 79% (95% CI: 64%, 89.5%), and the mean of kappa was
relatively low too, with a mean of 0.35 (95% CI: 0.08, 0.62).
The interobserver ICC to the total score was excellent
for AMSTAR at 0.84 (95% CI: 0.70, 0.91), and superior to
OQAQ, 0.67 (95% CI: 0.38, 0.82). The interrater agreement
(kappa) between two assessors for the global assessment
( i t e m1 0i nO Q A Q )w a s0 . 7 2( 9 5 %C I :0 . 4 8t o0 . 8 5 ) ,a n d
better than the self-developed 100-point rating scale: 0.50
(95% CI: 0.07–0.74).
3.2. Construct Validity. Total mean score was converted into
the percentage of the maximum score for each of the
instruments, the ICC for AMSTAR against OQAQ (total
score of 9 items, excluding item 10) was 0.87 (95% CI:
0.76, 0.93), that is, the results of AMSTAR were highly
convergence with the results of OQAQ. Besides, both overall
scoreswereconvertedintothepercentageofmaximumscore.
ICC obtained when comparing AMSTAR with the item 10 in
OQAQ was 0.84 (95% CI: 0.69, 0.91), and when comparing
withthe100-pointratingscale,ICCwasat0.81(95%CI:0.65
to0.90)respectively;thusAMSTARshowedwellconvergence
with global assessment instruments too.
In addition, we compared the total scores obtained by
applying AMSTAR on Cochrane reviews (n = 6, 8.42±1.02)
with that of non-Cochrane reviews (n = 35, 5.66 ± 1.31),
and the former had higher quality score than the latter
(mean diﬀerence = 2.76, P<0.001, 95% CI: 1.62, 3.90).
The relationship between quality scores and publish year
was explored too, reviews published after 2005 had similar
AMSTARscorescomparingtoearlierreviews(5.98±1.51ver-
sus 6.18±1.76, P = 0.70). As the methodological quality and
the reporting quality were not mutually exclusive addressing
in AMSTAR [8], we explored whether the number of pages
had a positive or negative eﬀect on the AMSTAR score,
the result showed there was a statistical association between
AMSTAR score and the number of pages (Spearman’s rho =
0.67, P<0.001).
3.3. Feasibility. It took 13.2 (95% CI: 12.2, 14.2) minutes to
complete use of AMSTAR for each review, while it took less
time to complete scoring of OQAQ, averagely 9.3 (95% CI:
8.8, 9.9) minutes per review (paired diﬀerence = 3.9, P<
0.001). Besides, a linear regression analysis was performed
(time = 6.35 + 2.94 × l a n g r a g e+1 .75 × log(pages), P<
0.001), revealed the time needed to complete using AMSTAR
had signiﬁcant associations with logarithm of the number of
pages (unstandardized coeﬃcients = 1.75, 95% CI: 0.61 to
2.90) and langrage (unstandardized coeﬃcients = 2.94, 95%
CI: 0.73 to 5.15); that is, systematic reviews with more pages
or written in English need more time to complete scoring.
The two assessors found there’s diﬃculty in approaching a
ﬁnal decision on item 9 “were the methods used to combine
the ﬁndings of studies appropriate” and item 5 “was a list
of studies (included and excluded) provided”; for the latter,
more detailed guidance for scoring “yes” are required.
4. Discussion
A considerable amount of systematic reviews on traditional
Chinese medicine have been conducted since the ﬁrst TCM
systematic review was published in the late 1990s [2, 3]. We
selected a random sample of TCM systematic reviews from
a database developed in a previous study [10], the sample
covered a wide variety of health topics, and thus, we believe
thatwehadarepresentativesampleofTCMreviewsofwhich
the AMSTAR was ready to apply.
Our ﬁndings in this research revealed that the AMSTAR
is a good choice for evaluating quality of TCM system-
atic reviews. The AMSTAR showed satisfactory interrater
agreement, convergent validity, and feasibility in assessing
methodological quality of TCM systematic reviews.
Interraterreliabilitywasevaluatedbyassessingthedegree
to which diﬀerent individuals agreed on the scientiﬁc quality
of a set of reports [7, 8] ,t h ep e r f o r m a n c eo fA M S T A Ri n
terms of agreement and reliability was better than that of4 Evidence-Based Complementary and Alternative Medicine
Table 1: Assessment of the interrater agreement for AMSTAR.
Item Agreement (%, 95% CI) Kappa (95% CI)
(1) Was an “a priori” design provided? 92.7 (80.1–98.5)
−0.03 (−0.10,
0.04)
(2) Was there duplicate study selection and data extraction? 85.4 (70.8–94.4) 0.70 (0.49, 0.91)
(3) Was a comprehensive literature search performed? 87.8 (73.8–95.9) 0.75 (0.55, 0.95)
(4) Was the status of publication (i.e., grey literature) used as an inclusion criterion? 95.1 (83.5–99.4) 0.72 (0.37, 1.00)
(5) Was a list of studies (included and excluded) provided? 48.8 (32.9–64.9) 0.16 (0.03, 0.30)
(6) Were the characteristics of the included studies provided? 78.1 (62.4–89.4) 0.40(0.08, 0.71)
(7) Was the scientiﬁc quality of the included studies assessed and documented? 92.7 (80.1–98.5) 0.36 (−0.20,
0.92)
(8) Was the scientiﬁc quality of the included studies used appropriately in formulating
conclusions? 92.7 (80.1–98.5) 0.36 (−0.20,
0.92)
(9) Were the methods used to combine the ﬁndings of studies appropriate? 56.1 (39.8–71.5) 0.17 (0.01, 0.33)
(10) Was the likelihood of publication bias assessed? 97.6 (87.1–99.9) 0.95 (0.85, 1.00)
(11) Were potential conﬂicts of interest included? 100 (91.4-100) 1.00 (1.00, 1.00)
Total 84 (71.1–91.9) 0.50 (0.26, 0.73)
OQAQ; overall agreement and kappa of items in AMSTAR
ranged from moderate to perfect, the reliability of its total
score was excellent. However, fair agreement and relatively
low kappa were observed in item 9 “were the methods used
to combine the ﬁndings of studies appropriate” and item
5 “was a list of studies (included and excluded) provided,”
indicated that there is a room for improvement on AMSTAR
when applying this new tool to assess methodological quality
of systematic reviews on TCM.
In the absence of a gold standard, we assessed construct
validity by comparing AMSTAR with OQAQ as well as
two global assessments. Construct validity was shown by
intraclass correlation coeﬃcient (ICC); this statistic reﬂects
the extent to which the results of AMSTAR converge with the
resultsofother“criterion”instruments.Theanalysisrevealed
that the construct validity was excellent, that is, the AMSTAR
is a reliable and valid tool. Given the extremely strict imple-
mentation of Cochrane systematic review, such reviews con-
ducted with high methodological quality have been widely
recognized [52]; the AMSTAR revealed Cochrane systematic
reviews have higher quality scores than non-Cochrane sys-
tematic reviews, that is, the AMSTAR has an ability to
discriminate methodological quality, so it is sensitive when
applying it to a sample of systematic reviews in diverse
quality. The relationship between AMSTAR quality score
and the number of pages can be explained by the fact that
Cochrane reviews always have considerable amount of pages,
these extreme outliers determined the direction and strength
of the association.
Compared with the results reported by Shea et al. [8],
considerable diﬀerences exists either on ICC for AMSTAR
contrast to the OQAQ, or on items with low kappa values.
Shea et al. reported a lower ICC of 0.66 (95% CI: 0.28, 0.84),
and diﬀerent items (item 4 and item 7) with relatively low
kappa parameter. Possible explanations for these diﬀerences
include (i) the diﬀerent samples of systematic reviews being
evaluated, most SRs in our sample were short, published in
Chinese, and more likely to be rated as low quality, such less
conversely evaluations could produce a higher ICC value in
our study; (ii) the extra procedure of translation and the
conductsofevaluationsbyapplyingtwotoolssimultaneously
may act as a kind of consensus training to make the
evaluations of AMSTAR more likely convergent with the
results of OQAQ, that lead to a higher ICC value too in the
present study; (iii) the background, skills, and expertise of
the assessors were diﬀerent from that of Shea et al. study.
Regarding the feasibility of AMSTAR, the time needed
to complete scoring showed this new tool is feasible in
assessing quality of TCM systematic reviews too; it took
about 13 minutes on average to complete an assessment and
showed well applicability. The statistical analysis revealed
that the AMSTAR was slightly more time consuming in
contrast to OQAQ; there may be several explanations for
this. First, the AMSTAR has 11 items, longer than the 10
items in OQAQ; second, the AMSTAR was developed based
on two instruments, including OQAQ itself, so items in the
instruments may be overlapped, and it would take less time
to complete scoring when ﬁlling replicated items; third, the
sequence of applying tools may be another explanation, as
we conducted the assessment in the order of ﬁrst AMSTAR
and then OQAQ, assessors need more time to look through
a systematic review to facilitate it in the ﬁrst round of
assessment by using AMSTAR, while in the second round by
applying OQAQ, such time would be saved.
The reliability analysis revealed that the Kappa was poor
to fair in some items on AMSTAR. As kappa coeﬃcient
shows the proportion of agreement beyond that expected by
chance alone, it is a popular measure for chance-corrected
nominal scale agreement between two raters [5, 8]; how-
ever, if distribution of item responses is skewed or over con-
centrated on either the “yes” or the “no” category, the kappa
coeﬃcients will become unstable and invalid, and no longer
suitable for measuring agreement between two raters, so
new methods for calculating valid agreement coeﬃcients are
needed to explore in future study. Such items shown in our
study included item 1 “was an ‘a priori’ design provided,”Evidence-Based Complementary and Alternative Medicine 5
item 6 “were the characteristics of the included studies
provided,” item 7 “was the scientiﬁc quality of the included
studies assessed and documented,” and item 8 “was the
scientiﬁcqualityoftheincludedstudiesusedappropriatelyin
formulating conclusions”; however, the relatively low kappa
in item 5 and item 9 cannot be explained by the limitation of
kappa statistic.
AMSTAR proved to be feasible to apply in quality as-
sessment of TCM systematic reviews; the main problems
emerged were the absence of guidance for certain item re-
sponse, such as item 5 “was a list of studies (included and
excluded) provided,” to get “yes” score, four situations may
be encountered: list of included studies provided, list of ex-
cluded studies provided, both lists of included and excluded
studies provided in the same time, and the characteristics
of the included studies presented; it is diﬃcult to reach a
ﬁnal conclusion without more detailed directions regarding
itsuse.Thoseitems(4and7)withrelativelylowkappavalues
identiﬁed by Shea et al. [8], on the contrast, presented more
precisely guidance, were easy to apply and easily reached
consensus among raters.
As the assessment was undertaken by two assessors, one
assessor was with expertise in clinical epidemiology and
clinical research methods, and the other was a novice user to
these quality assessment instruments, thus it could possibly
result in underestimation of the reliability of AMSTAR.
Another limitation in this study is lack of backward trans-
lation for the adapted tools, the translation into Chinese
may produce a diﬀerent measurement instrument with
diﬀerent properties. The current Chinese version should be
translated back into English by a third party, and the back
translations would be compared with the original tools to
ensure the conceptual equivalence. However, the absence of
back translation may oﬀset somewhat in present study by
a check of accuracy with a previous Chinese version of two
instruments tools [10].
5. Conclusions
Although both instruments proved to be useful in this study,
the performance of AMSTAR in terms of reliability and
validity was better than OQAQ; the new tool is reliable,
valid, and easy to use when applied to assess methodological
quality of systematic reviews on TCM, although there is
room for improvement on a few items.
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